MAPT and Alzheimer disease: With regard to p-tau217, mass spectrometry was found to have the best performance out of any other p-tau biomarker in detecting abnormal Aβ status and had strong predictive value for identifying patients with MCI and abnormal Aβ levels, and those who progressed to AD [83].